Myomo (MYO) Amortization of Deferred Charges (2020 - 2021)
Myomo (MYO) posted Amortization of Deferred Charges of -$99947.0 for Q2 2021, down 159.99% on a QoQ basis from $166600.0 in Q1 2021, and down 349.87% year-over-year from $40000.0 in Q2 2020.
Myomo (MYO) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends
Myomo's Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at -$99947.0 for Q2 2021.
- Quarterly Amortization of Deferred Charges fell 349.87% year-over-year to -$99947.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $78753.0 (down 26.49% YoY) and the FY2020 annual result came in at $161869.0, up 177.67% from the prior year.
- Amortization of Deferred Charges was -$99947.0 for Q2 2021 at Myomo, down from $166600.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $166600.0 in Q1 2021 and bottomed at -$99947.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Myomo | 43.43 Mn | 24.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -99,947.00 |
| Jun 30, 2021 | -99,947.00 |
| Mar 31, 2021 | 166,600.00 |
| Mar 31, 2021 | 166,600.00 |
| Sep 30, 2020 | 12,100.00 |
| Sep 30, 2020 | 12,100.00 |
| Jun 30, 2020 | 40,000.00 |
| Jun 30, 2020 | 40,000.00 |
| Mar 31, 2020 | 67,132.00 |
| Mar 31, 2020 | 67,132.00 |